Hemispherx Biopharma Aktie [WKN DE: A2PREX / ISIN: US00901B1052]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Hemispherx Biopharma Inc Registered Shs

12.12.24		AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue (GlobeNewswire)
06.12.24		Kellner Group Urges AIM Stockholders To Vote For Its Nominees To AIM Board (RTTNews)
19.09.24		AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination (RTTNews)
19.09.24		AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire)
09.05.24		AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast (GlobeNewswire)
06.05.24		AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® (GlobeNewswire)
29.04.24		AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire)
10.04.24		Aim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumab (RTTNews)
10.04.24		AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer (GlobeNewswire)
02.04.24		AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
26.03.24		AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast (GlobeNewswire)
25.03.24		AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire)
07.03.24		AIM ImmunoTech Announces Launch of CEO Corner Platform (GlobeNewswire)
29.02.24		AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update (GlobeNewswire)
14.02.24		AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pan (GlobeNewswire)
24.01.24		AIM ImmunoTech Gets Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligen (RTTNews)
24.01.24		AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire)
22.01.24		AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire)
10.01.24		AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
29.12.23		Delaware Court Rules In Favor Of AIM ImmunoTech, Upholds Activist Group's Board Nominations Invalid (RTTNews)
27.11.23		AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents (GlobeNewswire)
15.11.23		AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update (GlobeNewswire)
09.11.23		AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast (GlobeNewswire)
08.11.23		AIM ImmunoTech Announces Positive Data From Phase 2 Study Of Ampligen In Recurrent Ovarian Cancer (RTTNews)
17.10.23		AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs (GlobeNewswire)
27.09.23		Kognitiv Launches AI-Native Kognitiv Ignite: Revolutionary Outcome-Based Customer Engagement Solution (PR Newswire)
11.09.23		AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxe (GlobeNewswire)
15.08.23		AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update (GlobeNewswire)
09.08.23		AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast (GlobeNewswire)
08.08.23		Kognitiv Announces Sale of Hospitality Technology Business to Valsoft Corp. (PR Newswire)
08.08.23		AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
19.07.23		AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates (GlobeNewswire)
10.07.23		AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
27.06.23		AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research (GlobeNewswire)
27.06.23		AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s I (GlobeNewswire)
08.05.23		Kognitiv welcomes Jon Ott as Chief Revenue Officer (PR Newswire)
12.04.23		AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB) (GlobeNewswire)
03.04.23		AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
28.03.23		KOGNITIV LAUNCHES POWERFUL NEW AI-DRIVEN KOGNITIV PULSE (PR Newswire)
27.03.23		AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast (GlobeNewswire)
16.03.23		AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease (GlobeNewswire)
08.03.23		AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease (GlobeNewswire)
06.03.23		AIM ImmunoTech Issues Letter to Stockholders (GlobeNewswire)
17.01.23		AIM ImmunoTech Inks Pancreatic Cancer Clinical Research Deals With AstraZeneca, Erasmus (RTTNews)
14.11.22		AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Tr (GlobeNewswire)
31.10.22		AIM: Jorgl's Director Nominations To Be Disregarded At Annual Meeting On Court Ruling (RTTNews)
12.10.22		AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions (GlobeNewswire)
07.09.22		TRADE X Opens Its B2B Trading Platform to Automotive Buyers in the Dominican Republic (PR Newswire)
18.08.22		AIM ImmunoTech Commences Phase 2 Study Of Ampligen For Pancreatic Cancer Treatment (RTTNews)
18.08.22		AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer (GlobeNewswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Bullishe Aussichten: Das erwartet JPMorgan für den Goldpreis in 2025

Mayr-Melnhof startet im kommenden Jahr Aktienrückkauf - Aktie gewinnt deutlich

Lilium-Aktie zündet Kursrakete: Lilium kann neuen Investor von sich überzeugen

Bitcoin Kurs Prognose: BTC verliert 10 Prozent, jetzt schnell verkaufen?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.12.2024 14:42
Kaufwert:	EUR
	Hinzufügen Speichern